RU2722441C2 - Замещённые индольные соединения в качестве понижающих регуляторов рецепторов эстрогена - Google Patents

Замещённые индольные соединения в качестве понижающих регуляторов рецепторов эстрогена Download PDF

Info

Publication number
RU2722441C2
RU2722441C2 RU2018135203A RU2018135203A RU2722441C2 RU 2722441 C2 RU2722441 C2 RU 2722441C2 RU 2018135203 A RU2018135203 A RU 2018135203A RU 2018135203 A RU2018135203 A RU 2018135203A RU 2722441 C2 RU2722441 C2 RU 2722441C2
Authority
RU
Russia
Prior art keywords
equiv
compound
μmol
mmol
reaction solution
Prior art date
Application number
RU2018135203A
Other languages
English (en)
Russian (ru)
Other versions
RU2018135203A3 (cg-RX-API-DMAC10.html
RU2018135203A (ru
Inventor
Цзянью ЛУ
Чарльз З. Дин
Лихун ХУ
Хуэйцзюнь ХЭ
Шухуэй Чэнь
Цзяцян ДУН
Те-Линь ВАН
Original Assignee
Лосинь Фармасьютикал (Шанхай) Ко., Лтд.
Шаньдун Лосинь Фармасьютикал Груп Сток Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Лосинь Фармасьютикал (Шанхай) Ко., Лтд., Шаньдун Лосинь Фармасьютикал Груп Сток Ко., Лтд. filed Critical Лосинь Фармасьютикал (Шанхай) Ко., Лтд.
Publication of RU2018135203A3 publication Critical patent/RU2018135203A3/ru
Publication of RU2018135203A publication Critical patent/RU2018135203A/ru
Application granted granted Critical
Publication of RU2722441C2 publication Critical patent/RU2722441C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
RU2018135203A 2016-03-25 2017-03-24 Замещённые индольные соединения в качестве понижающих регуляторов рецепторов эстрогена RU2722441C2 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201610180518 2016-03-25
CN201610180518.7 2016-03-25
CN201610867918.5 2016-09-29
CN201610867918 2016-09-29
PCT/CN2017/078139 WO2017162206A1 (zh) 2016-03-25 2017-03-24 作为雌激素受体降解剂的吲哚并取代哌啶类化合物

Publications (3)

Publication Number Publication Date
RU2018135203A3 RU2018135203A3 (cg-RX-API-DMAC10.html) 2020-04-27
RU2018135203A RU2018135203A (ru) 2020-04-27
RU2722441C2 true RU2722441C2 (ru) 2020-06-01

Family

ID=59899253

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018135203A RU2722441C2 (ru) 2016-03-25 2017-03-24 Замещённые индольные соединения в качестве понижающих регуляторов рецепторов эстрогена

Country Status (11)

Country Link
US (1) US10519143B2 (cg-RX-API-DMAC10.html)
EP (1) EP3434668B1 (cg-RX-API-DMAC10.html)
JP (1) JP6790222B2 (cg-RX-API-DMAC10.html)
KR (1) KR102111792B1 (cg-RX-API-DMAC10.html)
CN (1) CN108884035B (cg-RX-API-DMAC10.html)
AU (1) AU2017239348B2 (cg-RX-API-DMAC10.html)
CA (1) CA3018801C (cg-RX-API-DMAC10.html)
ES (1) ES2821407T3 (cg-RX-API-DMAC10.html)
RU (1) RU2722441C2 (cg-RX-API-DMAC10.html)
SG (1) SG11201808363TA (cg-RX-API-DMAC10.html)
WO (1) WO2017162206A1 (cg-RX-API-DMAC10.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111032627B (zh) 2017-09-25 2023-10-20 罗欣健康科技发展(北京)有限公司 一种雌激素受体抑制剂的晶型及其制备方法
AU2019321588C1 (en) 2018-08-17 2026-05-14 Genentech, Inc. Diagnostic and therapeutic methods for the treatment of breast cancer
EP3889136B1 (en) * 2018-11-28 2024-12-18 Luoxin Pharmaceutical (Shanghai) Co., Ltd. Salt form of estrogen receptor downregulator, crystalline form thereof, and preparation method therefor
AU2019400398B2 (en) * 2018-12-17 2024-10-03 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Estrogen receptor antagonist
CN116891461B (zh) * 2022-03-30 2026-05-15 罗欣药业(上海)有限公司 一种serd中间体的合成方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA000815B1 (ru) * 1996-04-19 2000-04-24 Американ Хоум Продактс Корпорейшн Производные индола в качестве эстрогенных агентов
WO2012037411A2 (en) * 2010-09-16 2012-03-22 Aragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
WO2015136017A1 (en) * 2014-03-13 2015-09-17 F. Hoffmann-La Roche Ag Methods and compositions for modulating estrogen receptor mutants
WO2015136016A2 (en) * 2014-03-13 2015-09-17 F. Hoffmann-La Roche Ag Therapeutic combinations with estrogen receptor modulators

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100317635A1 (en) * 2009-06-16 2010-12-16 Endorecherche, Inc. Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
GB0917571D0 (en) 2009-10-07 2009-11-25 Karobio Ab Novel estrogen receptor ligands
US9499538B2 (en) * 2012-03-20 2016-11-22 Seragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA000815B1 (ru) * 1996-04-19 2000-04-24 Американ Хоум Продактс Корпорейшн Производные индола в качестве эстрогенных агентов
WO2012037411A2 (en) * 2010-09-16 2012-03-22 Aragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
WO2015136017A1 (en) * 2014-03-13 2015-09-17 F. Hoffmann-La Roche Ag Methods and compositions for modulating estrogen receptor mutants
WO2015136016A2 (en) * 2014-03-13 2015-09-17 F. Hoffmann-La Roche Ag Therapeutic combinations with estrogen receptor modulators

Also Published As

Publication number Publication date
CA3018801A1 (en) 2017-09-28
RU2018135203A3 (cg-RX-API-DMAC10.html) 2020-04-27
CN108884035A (zh) 2018-11-23
US20190106414A1 (en) 2019-04-11
ES2821407T3 (es) 2021-04-26
SG11201808363TA (en) 2018-10-30
US10519143B2 (en) 2019-12-31
EP3434668B1 (en) 2020-08-26
RU2018135203A (ru) 2020-04-27
EP3434668A4 (en) 2019-08-14
ES2821407T8 (es) 2022-02-02
CN108884035B (zh) 2020-03-13
WO2017162206A1 (zh) 2017-09-28
EP3434668A1 (en) 2019-01-30
KR102111792B1 (ko) 2020-05-18
AU2017239348B2 (en) 2020-03-12
JP2019512550A (ja) 2019-05-16
JP6790222B2 (ja) 2020-11-25
CA3018801C (en) 2020-06-23
KR20180128456A (ko) 2018-12-03
HK1256936A1 (zh) 2019-10-04
AU2017239348A1 (en) 2018-11-15

Similar Documents

Publication Publication Date Title
JP7266538B2 (ja) Fxr受容体作動薬としてのラクタム系化合物
WO2019085933A1 (zh) 作为Wee1抑制剂的大环类化合物及其应用
TWI250152B (en) N,N-substituted cyclic amine compounds used as calcium antagonizer
RU2727705C1 (ru) Производное бензопиперидина, способ его получения и его медицинское применение
CN110139863B (zh) 作为雌激素受体降解剂的吲哚并取代哌啶类化合物
TWI714566B (zh) 軸手性異構體及其製備方法和製藥用途
KR100250922B1 (ko) 교감신경 흥분 및 항빈뇨 활성을 갖는 에탄올아민 유도체
JP7237010B2 (ja) Hdac6選択的阻害剤およびその製造方法と使用
AU2017251555B2 (en) Pyridone derivative comprising heteroatomic ring butane substituent, for treating fibrosis and inflammatory diseases
JP6790222B2 (ja) エストロゲン受容体ダウンレギュレーターとしての置換インドール化合物
TW201625533A (zh) Kcnq 2至5通道活化劑
CN113896669B (zh) 雌激素受体调节剂及其用途
WO2019134662A1 (zh) 作为csf-1r抑制剂的杂环化合物及其应用
JP3231775B2 (ja) 心循環器系に作用する2−アミノ−1,2,3,4−テトラヒドロナフタレン誘導体、それらを製造する方法、及びそれらを含む医薬組成物
JP2010512339A (ja) Ampa受容体増強剤
CN107428682B (zh) 酰胺类衍生物、其制备方法及其在医药上的用途
JP7716980B2 (ja) エストロゲン受容体拮抗剤
WO2023280295A1 (zh) 一类苯并七元环类化合物及其应用
EP4508028B1 (en) Novel substituted 4-amino-4-oxo-but-2-enyl derivatives, processes for their preparation and therapeutic uses thereof
WO2019120198A1 (zh) 一类喹啉衍生物
CN120202198A (zh) 一种具有软药性质的硫醚类化合物、药物组合物及其用途
RU2772274C2 (ru) Селективные ингибиторы hdac6, способ их получения и их применение
BRPI0806888A2 (pt) Derivados de benzoquinazolina
HK1256936B (en) Substituted-indole compounds as estrogen receptor down-regulators
TW202440081A (zh) σ-1受體拮抗劑及其應用

Legal Events

Date Code Title Description
PC41 Official registration of the transfer of exclusive right

Effective date: 20220209